Audiocure Pharma Gmbh

Other

Ellneuroxx, Ltd.

Trommsdorff Gmbh & Co. Kg

Hans Rommelspacher

Rudy Susilo

Lidia Wlodek

Christoph Enzensperger

Tomasz Zygmunt

Reimar Schlingensiepen

The present invention relates to a stable crystalline polymorphic form of 6-fluoro-9-methyl-9H-β-carboline of formula (I) a method for preparation of said crystalline polymorphic form of 6-fluoro-9-methyl-9H-β-carboline, and a pharmaceutical composition comprising said crystalline polymorphic form of 6-fluoro-9-methyl-9H-β-carboline. Furthermore, the present invention relates to the use of said stable crystalline polymorphic form and the use of the pharmaceutical composition comprising said stable crystalline polymorphic form in the treatment and/or prophylaxis of hearing damage, vertigo or vestibular disorders.

Stable polymorphic form of 6-fluoro-9-methyl-9H-β-carboline and uses thereof

The present invention relates to fluoro-9-methyl-&#x3b2;-carbolines, their preparation as well as their medical use and pharmaceutical compositions containing fluoro-9-methyl-&#x3b2;-carbolines.

Fluoro-9-methyl-&#x3b2;-carbolines

The present invention is directed at &#x3b2;-carbolines, preferred 9-alkyl-&#x3b2;-carbolines (9-alkyl-&#x3b2;-BC), their manufacture as well as their use in prophylaxis and treatment of hearing damages, tinnitus, acute acoustic trauma, vertigo and vestibular disorder as well as pharmaceutical compositions containing theses &#x3b2;-carbolines.

Beta-carbolines for use in the treatment of hearing loss and vertigo

The embodiments relate to derivatives of 9-alkyl-&#x3b2;-carboline, their production and pharmaceutical compositions containing these 9-alkyl-&#x3b2;-carboline derivatives. Further, the use of 9-alkyl-&#x3b2;-carboline derivatives and pharmaceutical compositions for the treatment and prevention of movement disorders, neurodegenerative diseases, Alzheimer's disease and Parkinson's disease is described. Additionally, these effects can be utilized for the cultivation of cells such as dopaminergic cells or stem cells which shall be engrafted for the treatment of Parkinson's disease.

&#x3b2;-carboline for the treatment of neurodegenerative diseases

Use of 2-methyl-thiazolidine-2,4-dicarboxylic acid (2-MTDC) and/or its physiologically tolerable salts for the treatment and/or prevention of cancer.

Use of 2-methyl-thiazolidine-2,4-dicarboxylic acid and/or physiologically compatible salts thereof for producing a medicament for treating cancers

This invention relates to a pharmaceutical containing a combination of 2-methyl-thiazolidine-2,4-dicarboxylic acid and paracetamol, and to the use of a combination of 2-methyl-thiazolidine-2,4-dicarboxylic acid and paracetamol as an analgesic and/or antipyretic.

Combined preparation consisting of 2-methylthiazolidine-2,4-dicarboxylic acid and paracetamol

This invention relates to the use of 2-methyl-thiazolidine-2,4-dicarboxylic acid and/or its physiologically tolerable salts as mucolytic agents.

Growing community of inventors

Berlin, Germany

Hans Rommelspacher